Blog

Leiden, 9 April  2026 – BIMINI Biotech is pleased to announce that the MYELO-WASP project has been awarded funding through the Eureka Eurostars programme, supporting the development of first-in-class small molecules targeting the Wiskott–Aldrich Syndrome Protein (WASp) for the treatment of myeloid and lymphoid leukemias. The international project brings together a strong consortium of partners:…
Lees meer

Leiden, January 8th, 2025 – BIMINI Biotech, an innovative Leiden-based drug development company that develops novel therapeutics for hematological cancers, successfully closed a seed investment round of EUR 3 million. The round was led by San Diego-based (US) Torrey Pines Investment (“TPI”), with the participation of InnovationQuarter Capital (“IQC”), Libertatis Ergo Holding (“LEH”) and a…
Lees meer

BIMINI Biotech has received a MIT feasibility grant (€20.000) for the AUTO-WASP project. The Mkb-innovatiestimulering Regio en Topsectoren (MIT) stimulates innovation in small and medium-sized enterprises across regional borders. In addition, MIT encourages SME projects to better align with the knowledge and innovation agendas of the Missions for the future. This enables companies to carry…
Lees meer

Leiden, 29 June 2023 – BIMINI Biotech, an innovative Leiden-based therapeutics start-up that develops novel therapeutics for hematological cancers, raised an additional investment of €250,000 from lead investor Libertatis Ergo Holding B.V. (LEH). The investment will be used in combination with a recently awarded Eurostars grant to progress the preclinical development of our lead candidates…
Lees meer

Leiden, 1 April 2023 – BIMINI Biotech, an innovative therapeutics startup, was recently awarded a Eureka Eurostars project with the aim of developing novel therapeutics for lymphomas. This project named HEMATO-WASP, brings together a unique consortium consisting of BIMINI Biotech (Leiden, the Netherlands), InnoSer Nederland (Leiden, the Netherlands) and the Institute of Oncology Research (IOR;…
Lees meer